115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)
  7. Center for Hematologic Malignancies (13261)
  8. Hematologic Malignancies, Division of (13086)
  9. Sloan Kettering Institute Postdocs (12935)
  10. Department of Pathology and Laboratory Medicine (12608)
Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)

More Groups

People
  1. Marc Ladanyi (1326)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1049)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Final analysis of multi-histology basket trial expansion of ado-trastuzumab emtansine in patients with HER2 amplified cancers
    Meeting Abstract

    Liu, D.; Makker, V.; Buonocore, D. J.; Shen, R.; Yaeger, R.; Ginsberg, M. S.; Yeh, R.; Johnson, A.; Offin, M.; Solit, D. B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study
    Meeting Abstract

    Moore, K. N.; Sabanathan, D.; Du, Y.; Duan, H.; Li, X.; Wang, F.; Marathe, O.; Yang, H.; Makker, V.; Growdon, W.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1/2a study
    Meeting Abstract

    De La Fuente, M. I.; Rodon Ahnert, J.; Yaeger, R.; Tsai, F. Y. C.; Janku, F.; Butowski, N. A.; Allen, C. E.; Ammakkanavar, N. R.; Taylor, . W.; Michelson, G.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A first-in-human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors
    Meeting Abstract

    Drilon, A. E.; Johnson, M. L.; Gadgeel, S. M.; Nepert, D.; Feng, G.; Golmakani, M.; Reddy, M.; Harney, A.; Oliver, C.; Mills, B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer
    Meeting Abstract

    Yap, T. A.; Elhaddad, A. M.; Grisham, R. N.; Hamm, J. T.; Marks, D. K.; Shapiro, G.; Le Corre, C.; Li, J.; Lin, T. T.; Liu, F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase II randomized trial of talimogene laherparepvec (T-VEC) oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors
    Meeting Abstract

    Barker, C. A.; D'Angelo, S. P.; Steckler, A. M.; Lian, M.; Wasilewski, G.; Lacouture, M. E.; Chapman, P. B.; Shoushtari, A. N.; Ariyan, C. E.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A novel method that leverages existing data to conduct comparative analyses of competing assets: Sugemalimab and agents targeting the PD-L1/PD-1 axis as an example
    Meeting Abstract

    Fojo, A. T.; Zhou, M.; LaRose, M.; Bates, S. E.; Schwartz, L. H.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Fecal microbiota transplantation for refractory immune-checkpoint-inhibitor colitis
    Meeting Abstract

    Elkrief, A.; Nicholas, W.; Smith, N.; Dai, A.; Slingerland, J. B.; Aleynick, N.; Lumish, M. A.; Giardina, P.; Chaft, J. E.; Chapman, P. B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate, in patients with small cell lung cancer
    Meeting Abstract

    Morgensztern, D.; Ready, N. E.; Johnson, M. L.; Dowlati, A.; Choudhury, N. J.; Carbone, D. P.; Schaefer, E. S.; Arnold, S. M.; Puri, S.; Piotrowska, Z.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL)
    Meeting Abstract

    Locke, F. L.; Lekakis, L. J.; Eradat, H.; Munoz, J.; Tees, M. T.; de Vos, S.; Nath, R.; Stevens, D. A.; Malik, S.; Popplewell, L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save